The case against former Oklahoma death row inmate Richard Glossip is moving forward once again. Glossip was facing execution for the 1997 murder of his boss, Barry Van Treese. Earlier this year, the U ...
Cloudflare has open-sourced tokio-quiche, an asynchronous QUIC and HTTP/3 Rust library that wraps its battle-tested quiche ...
The leaked internal chat communications of the Black Basta ransomware group offer an unprecedented view into how cybercriminals operate, plan attacks, and ...
Before market open, Recursion divulged that its REC-4881 demonstrated notable efficacy in a phase 1b/2 trial. The drug, which treats a disorder called familial adenomatous polyposis (FAP) in which ...
It was Friday afternoon, and I'd just hit send on my weekly report to Amazon's Retail vice presidents, detailing what the Global Merchandising team I'd created had accomplished that week. I was 38, ...
After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...
Multiple factors contribute to a positive patient experience, says the new CMO of AdventHealth Altamonte Springs. They include effective communication with patients, the hospital environment, food ...
President Trump rated his highly anticipated sit down with Chinese leader Xi Jinping a 12 out of 10. WSJ’s Alexander Ward explains why. Photo: Yonhap/EPA/Shutterstock In an unusual diplomatic move, ...
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...
Grand Theft Auto Ex-Rockstar dev doesn't believe GTA 6 will be delayed again: "The hype around the game will die down" Grand Theft Auto GTA Tokyo nearly happened until the idea fizzled out: "It ...
Recursion Pharmaceuticals, Inc. leverages AI to accelerate drug discovery, offering both a licensing platform and an internal drug development pipeline. RXRX faces heavy competition, ongoing operating ...
After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback